Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of trastuzumab rezetecan in HER2-mutated or HER2-low solid tumors after failure of standard treatment
ChiCTR2600128885Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab rezetecan in biliary cancer, gastrointestinal cancer, transitional cell carcinoma (TCC) and 3 more (6 cohorts), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Objective response rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
biliary cancergastrointestinal cancertransitional cell carcinoma (TCC)head and neck cancer (HNC)gynecological cancer
Beyond the preview
Go deeper on ChiCTR2600128885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128885.